Brought to you by 
Hydra Biosciences grosses $18.9mm with financing
03 Feb 2004
Executive Summary
Hydra Biosciences (molecular regeneration medicines) has raised $18.9mm with its Series B private placement of shares. Lead investor Lilly BioVentures was joined by new backer BioVentures Investors and returning participants Polaris Venture Partners, Abingworth, New Enterprise Associates, Advanced Technology Ventures, and Boston Medical Investors. Abbott Laboratories also participated as part of its 2002 proliferative vascular disease agreement with Hydra Biosciences.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hydra Biosciences grosses $18.9mm with financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice